The 10 most recent market catalysts affecting $ENTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 65
Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Guggenheim analyst Vamil Divan initiated coverage on Entera Bio (ENTX) with a 'Buy' rating and an $11 price target. This event is significant because new analyst coverage, especial…
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 55
Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Cantor Fitzgerald's initiation of coverage on Entera Bio (ENTX) with an Overweight rating is a positive development for the company. Analyst coverage, especially from a reputable f…
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 55
Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9
Leerink Partners initiating coverage on Entera Bio with an Outperform rating and a $9 price target is a positive development for the company. Analyst coverage can increase visibili…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 55
Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement
Entera Bio has filed a prospectus to register the resale of a significant number of ordinary shares (up to 134,803,910) by existing selling shareholders. These shares originated fr…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 65
Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
Entera Bio (ENTX) is providing an update on its drug development pipeline, specifically for EB612 and EB613. The intention to file an IND for EB612 in H1 2027 and the planned initi…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 65
Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting
Entera Bio (ENTX) announced that post-hoc data from its Phase 2 trial of EB613, an oral anabolic treatment for osteoporosis, will be presented at the prestigious ASBMR 2026 Annual …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
Entera Bio secured a substantial $275 million through an oversubscribed private placement, a critical event for a biotech company. This financing is pivotal as it fully funds the P…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 85
Entera Bio shares are trading higher after the company announced pricing of oversubscribed $275 million private placement.
This headline is a significant corporate catalyst for Entera Bio (ENTX). The oversubscribed nature of the $275 million private placement signals strong investor demand and confiden…
Jul 27, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Monday's Intraday Session
This 8-K filing, generated by Benzinga's automated content engine, simply reports on the intraday stock price performance of 12 health care companies. It does not disclose any spec…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 95
Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Entera Bio announced an oversubscribed private placement, raising approximately $275 million. This capital infusion is a major positive catalyst for ENTX, as it provides the necess…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.